New combo approach targets EGFR lung cancer with promising drug
NCT ID NCT06194448
First seen Nov 04, 2025 · Last updated May 21, 2026 · Updated 30 times
Summary
This study tests whether giving the targeted drug osimertinib before and after standard chemoradiation helps adults with a specific type of stage III lung cancer (EGFR mutation-positive) that cannot be removed by surgery. About 76 participants will receive osimertinib first, then chemoradiation, then continue osimertinib to keep the cancer under control. The goal is to see if this approach delays cancer growth and is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
La Jolla, California, 92093, United States
-
Research Site
Palo Alto, California, 94304, United States
-
Research Site
Beijing, 100021, China
-
Research Site
Changsha, 410013, China
-
Research Site
Guangzhou, 510060, China
-
Research Site
Hangzhou, 310022, China
-
Research Site
Harbin, 150081, China
-
Research Site
Hefei, 230001, China
-
Research Site
Jinan, 250117, China
-
Research Site
Nanning, 530021, China
-
Research Site
Shanghai, 200032, China
-
Research Site
Tianjin, 300060, China
-
Research Site
Wuhan, 430022, China
-
Research Site
Wuhan, 430071, China
-
Research Site
Zhengzhou, 450052, China
-
Research Site
Haifa, 31096, Israel
-
Research Site
Jerusalem, 91031, Israel
-
Research Site
Tel Aviv, 62748, Israel
-
Research Site
Cheongju-si, 28644, South Korea
-
Research Site
Seongnam-si, 13620, South Korea
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
Suwon, 16247, South Korea
-
Research Site
Barcelona, 08003, Spain
-
Research Site
Donostia / San Sebastian, 20014, Spain
-
Research Site
Granada, 18016, Spain
-
Research Site
Madrid, 28007, Spain
-
Research Site
Tainan, 704, Taiwan
-
Research Site
Taipei, 11217, Taiwan
-
Research Site
Bangkok, 10210, Thailand
-
Research Site
Bangkok, 10330, Thailand
-
Research Site
Chiang Rai, 57000, Thailand
-
Research Site
Hat Yai, 90110, Thailand
-
Research Site
Khon Kaen, 40002, Thailand
-
Research Site
Ankara, 06010, Turkey (Türkiye)
-
Research Site
Yenimahalle, 06560, Turkey (Türkiye)
-
Research Site
Hanoi, 100000, Vietnam
-
Research Site
Ho Chi Minh City, 700000, Vietnam
Conditions
Explore the condition pages connected to this study.